期刊文献+

口腔黏膜黑色素瘤人源性移植瘤模型的建立及鉴定 被引量:1

Establishment and validation of patient-derived xenograft model of oral mucosal melanoma
下载PDF
导出
摘要 目的:建立和鉴定口腔黏膜黑色素瘤(oral mucosal melanoma,OMM)人源性移植瘤(patient-derived xenograft,PDX)模型。方法:将4例原发性口腔黏膜黑色素瘤组织移植于免疫缺陷裸鼠皮下,观察并记录裸鼠成瘤情况,待移植瘤稳定生长后进行传代;利用H-E染色观察原发瘤和移植瘤的组织病理学特征,应用免疫组织化学染色检测黑色素瘤标志物HMB-45、Melan-A、S-100及Ki-67在两者组织的表达水平。结果:4例口腔黏膜黑色素瘤组织皮下移植成功并序列传代;H-E和免疫组织化学染色显示,移植瘤在组织病理形态和4个标志物表达情况上与原发瘤保持一致。结论:本研究成功建立4例口腔黏膜黑色素瘤人源性移植瘤模型,传代移植瘤保留了原发瘤的组织病理学和分子特征,可为口腔黏膜黑色素瘤研究提供理想的临床前动物模型。 PURPOSE: To establish and validate patient-derived xenograft (PDX) model of oral mueosal melanoma (OMM). METHODS: Four primary OMM specimens were implanted into immune-deficient nude mice subcutaneously, the mice were evaluated for tumor growth, stable xenograft tumor models and were passaged. Histopathologieal characteristics were observed by H-E staining. OMM-associated clinical markers (HMB-45, Melan-A, S-100 and Ki-67) were detected by immunohistochemistrical staining. RESULTS: OMM samples from 4 patients were implanted subcutaneously and passaged for expansion successfully. Histopathologically and immunohistochemistrieally, PDX models showed similar morphology and HMB-45, Melan-A, S-100 and Ki-67 protein expression to the primary tumor. CONCLUSIONS: Four xenograft models were successfully established, in which the histopathologieal and molecular features of the primary tumors are preserved through passaging, which provid promising preelinical models for translational research of OMM.
出处 《中国口腔颌面外科杂志》 CAS 2017年第6期481-487,共7页 China Journal of Oral and Maxillofacial Surgery
基金 国家自然科学基金(81572656)
关键词 口腔黏膜黑色素瘤 人源性移植瘤模型 裸鼠 Oral mueosal melanoma Patient-derived xenograft model Nude mice
  • 相关文献

参考文献5

二级参考文献103

  • 1Fecher LA,Cummings SD,Keefe MJ,et al.Toward a molecular classification of melanoma[J].J Clin Oncol,2007,25(12):1606-1620.
  • 2Curtin JA,Fridlyand J,Kageshita T,et al.Distinct sets of genetic alterations in melanoma[J].N Engl J Med,2005,353(20):2135-2147.
  • 3Curtin JA,Busam K,Pinkel D,et al.Somatic activation of KIT in distinct subtypes of melanoma[J].J Clin Oncol,2006,24(26):4340-4346.
  • 4Minoru T,Toshiaki S.Genetic alterations in melanocytic tumors[J].Journal of Dermatological Science,2006,43(1):1-10.
  • 5Cruz F 3rd,Rubin BP,Wilsom D,et al.Abesence of BRAF and NRAS mutations in uveal melanoma[J].Cancer Res,2003,63(18):5761-5766.
  • 6Beading C,Erick JD,Hodi FS,et al.Kit gene mutations and copy number in melanoma subtypes[J].Clin Cancer Res,2008,14(21):6821-6828.
  • 7Brose MS,Volpe P,Feldman M,et al.BRAF and RAS mutation in human lung cancer and melanoma[J].Cancer Res,2002,62(12):6997-7000.
  • 8Ball NJ,Yohn JJ,Morelli JG,et al.RAS mutations in human melanoma:a marker of malignant progression[J].J Invest Dermatol,1994,102(3):285-290.
  • 9Went PT,Dirnhofer S,Bundi M,et al.Prevalence of KIT expression in human tumors[J].J Clino Oncol,2004,22(22):4514-4522.
  • 10Antonescu CR,Busam KJ,Francone TD,et al.L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitiv to specific kinase inhibition[J].Int J Cancer,2007,121(2):257-264.

共引文献53

同被引文献7

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部